Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effects of aspirin versus aspirin plus low-dose rivaroxaban on carotid atherosclerotic plaque inflammation
KCT0005515Phase 4Completed
- Sponsor
- Bayer
- Start
- Aug 2021
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of aspirin and rivaroxaban in coronary arteriosclerosis, arteriosclerosis obliterans and carotid atheroma (CAS) (2 arms), sponsored by Bayer. Primary endpoint: Change in carotid atherosclerotic plaque inflammation. Started Aug 2021; status: completed.
02
Drugs
aspirinrivaroxaban
03
Conditions
coronary arteriosclerosisarteriosclerosis obliteranscarotid atheroma (CAS)
Beyond the preview
Go deeper on KCT0005515.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0005515.